Gedeon Richter Plc, commonly referred to as Richter, is a prominent global pharmaceutical company headquartered in Hungary (HU). Founded in 1901, the company has established a strong presence in various operational regions, including Europe, Asia, and North America. Specialising in women's health, central nervous system disorders, and generic pharmaceuticals, Richter is renowned for its innovative approach to drug development. The company’s core products include hormonal contraceptives and treatments for infertility, which are distinguished by their high quality and efficacy. Over the years, Gedeon Richter has achieved significant milestones, including strategic partnerships and a robust pipeline of new therapies. With a commitment to research and development, Richter has solidified its position as a key player in the global pharmaceutical market, recognised for its contributions to healthcare and patient well-being.
How does Gedeon Richter's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Gedeon Richter's score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Gedeon Richter reported total carbon emissions of approximately 197,000,000 kg CO2e in Hungary. Globally, their emissions reached about 289,000,000 kg CO2e, which includes 60,777,000 kg CO2e from Scope 1, 84,557,000 kg CO2e from Scope 2, and 143,779,000 kg CO2e from Scope 3 emissions. This marks a decrease from 2022, when emissions in Hungary were about 213,000,000 kg CO2e and globally about 295,000,000 kg CO2e. Gedeon Richter has set ambitious climate commitments, aiming to reduce overall greenhouse gas emissions by 55% by 2030, with a baseline year of 2020. Specifically, they plan to cut Scope 1 emissions by 30% and Scope 2 emissions by 30% from the same baseline by 2030. Additionally, they aim to reduce Scope 1 and Scope 2 emissions to near zero by 2025. The emissions data is sourced from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., with no cascaded data from parent companies. Gedeon Richter's commitment to sustainability reflects a proactive approach to addressing climate change within the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Scope 1 | 37,359,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 73,452,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 104,973,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gedeon Richter is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.